Coulter Partners strengthens leadership at IMU Biosciences with placements of Chief Executive Officer and Chief Business Officer

IMU Biosciences is a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine.

Dr. Adam Laing, President and CSO of IMU Biosciences, commented: “I am incredibly proud of what the IMU team has achieved to date. We have built a powerful platform that has the potential to revolutionize precision medicine across a range of health conditions. I look forward to continuing to advance our scientific strategy and innovation, and to working closely with John and Jason to realize the full potential of our immune-powered approach.”

He went on to say, “We are incredibly grateful to Coulter Partners for their invaluable assistance in finding two exceptional leaders to join our team. Their expertise in executive search was instrumental in identifying candidates who not only possess the necessary skills and experience but also align perfectly with our company's culture and vision.”

‍Dr. John Baker, incoming Chief Executive Officer at IMU Biosciences, added: “I am excited to join IMU Biosciences at a pivotal moment. The Company's unique approach to immune profiling has huge potential, and I'm looking forward to guiding its continued growth and development. IMU's proprietary technology platforms have the ability to meaningfully impact patient outcomes. Together with Adam, Jason, and the full IMU team, our mission is to advance our pipeline, forge strategic partnerships, and ultimately drive the delivery of life-changing therapies to patients.”

----

Dr. John Baker, PhD, Chief Executive Officer

John Baker joins IMU Biosciences from Abcam, a global life science tools company, where he most recently served as Senior Vice President, Supply Chain and Manufacturing. John has been on the Executive Team at Abcam since 2016, during which time the business delivered exceptional growth, culminating in a successful acquisition for c. $5.7 billion and transition into Danaher Corporation in 2023. During his time at Abcam, John led global teams spanning Business Development, R&D, Product, Marketing, and Supply Chain & Manufacturing. John trained as a veterinarian, undertaking both his undergraduate and clinical training in Cambridge. Following a spell in commercial animal practice, John moved to Oxford for a DPhil in Clinical Medicine, publishing on the molecular biology of the innate immune response. John spent 6 years with Bain and Company in London, where he was a leader in the company’s Global Healthcare Practice. He has previously held Non-Executive Director roles at both BrickBio and Somaserve.

Dr. Jason Brown, PhD, Chief Business Officer

Jason Brown joins IMU Biosciences from Evotec, a leading R&D biotech company, where he served as Senior Vice President of Business Development. Jason brings a wealth of expertise in business development, scientific discovery partnerships, and drug discovery services. Previous roles include founding and leading Ubiquigent, a specialized drug discovery services company in the protein degradation field, where he secured key partnerships and drove scientific innovation. Jason completed a PhD at the University of Cambridge, leading research which resulted in the identification of the molecular target of the blockbuster Pfizer drugs Neurontin™ and Lyrica®. As IMU Biosciences’ first Chief Business Officer, Jason will oversee the Company’s business development and partnering efforts.

About IMU Biosciences

About Coulter Partners